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ABSTRACT
Background: Low-dose aspirin is the most common drug used for prevention of cardiovascular and cerebrovascular 
events. Long-term aspirin therapy can induce gastroduodenal mucosal injury, even in a very low dose (10 mg daily). 
The frequency of gastroduodenal injuries among long-term low-dose aspirin users in Indonesia is currently unknown. 
The aim of this study is to determine the prevalence of gastroduodenal mucosal injury, endoscopic findings, and 
influencing factors among long-term low-dose aspirin users in Cipto Mangunkusumo Hospital.
Method: This study was a cross-sectional study conducted in Cipto Mangunkusumo Hospital, Jakarta. 
Subjects were patients aged ≥ 18 years old who had been using low-dose aspirin (75-325 mg) for at least the 
preceding 28 days. Ninety-five subjects were recruited consecutively in the period of December 2015 – April 
2016. History taking, upper endoscopic examination, and histopathology examination for Helicobacter pylori 
infection were performed in all subjects. Endoscopic findings such as erosions and ulcers were assessed as 
mucosal injuries. Data were analysed to find prevalence, bivariate analysis (Chi-square test), and multivariate 
analysis (logistic regression test).
Results: Mucosal injury was found in 49 subjects (51.6%; 95% CI: 41.6–61.7%), mucosal erosion in 38 
subjects (40%; 95% CI: 30.2–49.9%) and ulcers in 11 subjects (11.6%; 95% CI: 5.2–18.0%). Only 44.9% patients 
with mucosal injury had dyspepsia symptoms. Double antiplatelet therapy increased the risk of mucosal injury 
(OR = 3.3; 95% CI: 1.3–8.5). However, proton pump inhibitor (PPI) decreased the risk of mucosal injury (OR 
= 0,2; 95% CI: 0,04 – 0,60).
Conclusion: Gastroduodenal mucosal injury was found in more than half of long-term low-dose aspirin 
users. Double antiplatelet therapy increased the risk of mucosal injury, while PPI effectively reduced the risk.
Keywords: low-dose aspirin, gastroduodenal mucosal injury, endoscopy
ABSTRAK
Latar belakang: Aspirin dosis rendah adalah obat profilaksis kejadian kardiovaskular yang paling sering 
digunakan. Efek samping gastroduodenal sering terjadi pada penggunaan aspirin jangka panjang, bahkan 
pada dosis yang sangat rendah (10 mg/hari). Saat ini angka kejadian kerusakan mukosa gastroduodenal akibat 
penggunaan aspirin dosis rendah jangka panjang di Indonesia belum diketahui.
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Tujuan: Mengetahui besarnya prevalensi dan gambaran endoskopi kerusakan mukosa gastroduodenal pada 
pengguna aspirin dosis rendah jangka panjang pada pasien yang berobat di Rumah Sakit Cipto Mangunkusumo 
(RSCM), serta faktor-faktor yang mempengaruhi.
Metode: Penelitian ini menggunakan desain potong lintang. Sampel penelitian adalah pasien poliklinik dan 
ruang perawatan RSCM usia ≥ 18 tahun yang mengkonsumsi aspirin dosis rendah (75-325 mg) lebih dari 28 
hari. Didapatkan 95 subjek penelitian melalui metode konsekutif dalam periode Desember 2015 hingga April 
2016. Pasien dilakukan anamnesis, pemeriksaan endoskopi saluran cerna atas, dan pemeriksaan histopatologi 
untuk menilai adanya infeksi Helicobacter pylori. Temuan endoskopi berupa erosi mukosa dan ulkus peptikum 
dimasukkan ke dalam kelompok kerusakan mukosa. Data diolah untuk memperoleh proporsi, analisis bivariat 
(uji Chi-square), dan analisis multivariat (uji regresi logistik).
Hasil: Kerusakan mukosa gastroduodenal ditemukan pada 49 subjek (51,6%; 95% CI: 41,6-61,7%), dengan 
gambaran erosi mukosa pada 38 subjek (40%; 95% CI: 30,2-49,9%) dan ulkus peptikum pada 11 subjek (11,6%; 
95% CI: 5,2-18,0%). Hanya 44.9% pasien dengan kerusakan mukosa gastroduodenal yang memiliki keluhan 
dispepsia. Kombinasi antitrombotik meningkatkan risiko terjadinya kerusakan mukosa dengan OR = 3,3 (95% 
CI: 1,3-8,5). Sedangkan penggunaan obat golongan proton pump inhibitors (PPI) menurunkan risiko kerusakan 
mukosa (OR = 0,2; 95% CI: 0,04-0,60).
Simpulan: Kerusakan mukosa gastroduodenal terjadi pada lebih dari separuh pasien yang menggunakan 
aspirin dosis rendah jangka panjang. Kombinasi anti-trombotik meningkatkan risiko kerusakan mukosa. 
Sedangkan penggunaan PPI efektif dalam menurunkan risiko tersebut.
Kata kunci: aspirin dosis rendah, kerusakan mukosa gastroduodenal, endoskopi
INTRODUCTION
Low-dose aspirin (acetylsalicylic acid or ASA) (75-
325 mg) is the most frequently used prophylactic drugs 
for cardiovascular and cerebrovascular events.1,2,3 Use 
of aspirin can decrease 10-20 per 1,000 cardiovascular 
events and also mortality rates due to vascular diseases.1 
Administration of this drug increases globally as the 
rate of life expectancy improves.4 In clinical setting, 
the most important and frequent side effects of aspirin 
administration is gastrointestinal side effects, ranging 
from mucosal erosion to bleeding which may lead to 
death.5 Even the very low-dose aspirin (10 mg per day) 
can decrease gastric mucosal prostaglandin level which 
causes significant injury to gastric mucosa.6
Based on previous studies, mucosal erosion took 
place in approximately 60% of aspirin users, while 
peptic ulcer was found in 11-19% patients.7,8 However, 
more studies associated the use of aspirin with 
gastrointestinal bleeding.9-14 In a large study involving 
27,694 patients, upper gastrointestinal bleeding was 
found in 2.6% of aspirin users.15 But, clinical symptom 
does not always present in mucosal injury due to aspirin 
administration.7,16 Therefore, endoscopic examination 
of upper gastrointestinal tract should be performed 
in long-term low-dose aspirin users regardless of the 
presence of clinical complaints.
Incidence of non-variceal gastroduodenal bleeding 
in Indonesia is quite high. Among 4,154 patients 
who underwent endoscopic examination of upper 
gastrointestinal tract in year 2001 to 2005 in Cipto 
Mangunkusumo Hospital, it was found that 837 
patients (20.15%) suffered from upper gastrointestinal 
bleeding and most of them were non-variceal 
(66.6%).17 The same researcher in year 2008 reported 
higher incidence of gastric and duodenal ulcer in non-
steroidal anti-inflammatory drugs (NSAIDs) users 
compared to control group.18 Meanwhile, there is no 
available data regarding prevalence of gastroduodenal 
mucosal injury in long-term low-dose aspirin users in 
Indonesia yet.
METHOD
This study used cross-sectional design. Samples 
of this study were polyclinic and hospitalized patients 
in Cipto Mangunkusumo Hospital aged ≥ 18 years 
old who consumed low-dose aspirin (75-325 mg) for 
more than 28 days without considering the presence of 
dyspepsia symptoms. We obtained 95 study subjects 
through consecutive sampling method in the period of 
December 2015 – April 2016. Patients who underwent 
coronary stent placement in the last 6 months, those 
who had undergone gastrectomy, or those who refused 
endoscopic examination were excluded from this study. 
Patients’ data were collected through direct history 
taking with patients included in the study. Endoscopic 
examination was performed in Gastrointestinal 
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Endoscopy Centre, Cipto Mangunkusumo Hospital. 
Histopathology examination was performed in Anatomy 
Pathology Laboratory, Cipto Mangunkusumo Hospital.
Endoscopic findings in the form of mucosal erosion 
and peptic ulcer were included in mucosal injury group. 
Independent variables which were being analysed 
include age, antithrombotic combination, combination 
with anticoagulant, combination with other NSAIDs, 
Helicobacter pylori (H pylori) infection, diabetes mellitus, 
and PPI administration. Data was analysed to obtain 
the proportion, bivariate analysis (Chi-square test), and 
multivariate analysis (regression logistic test). This study 
had received approval from ethical committee and all 
research subjects had signed written informed consent. 
RESULTS
Based on the endoscopy results of upper 
gastrointestinal tract, gastroduodenal mucosal injury 
was found in 49 patients (51.6%; 95% CI: 41.6-61.7%), 
with erosive gastritis appearance in 38 patients (40%; 
95% CI: 30.2-49.9%) and peptic ulcer in 11 patients 
(11.6%; 95% CI: 5.2-18.0%). Through Kolmogorov 
Smirnov test, we found normal distribution data of age, 
with average of 63.5 ± 7.7 years old. Majority patients 
were male 61 patients (64.2%). There were 49 patients 
(51.6%) who suffered from dyspepsia complaints 
while the remaining 46 patients were asymptomatic. 
In the group of patients whose upper gastrointestinal 
endoscopic results revealed mucosal injury appearance, 
we found 57.1% patients whose age were above 65 
years old; 40.8% used antithrombotic combination; 
4.1% used warfarin; 8.2% used NSAIDs; 8.2% suffered 
from H. pylori infection; and 38.8% suffered from 
diabetes mellitus. Description of characteristics of 
research subjects was shown in Table 1.
In this study, there were 6 risk factors which were 
analysed as risk factors of gastroduodenal mucosal 
injury in patients who consumed low-dose aspirin for 
more than 28 days, including age, use of antithrombotic 
combination, use of warfarin, use of NSAIDs, H. 
pylori infection, and diabetes mellitus. Proportion of 
independent variables in gastric mucosal injury group 
and normal mucosa group can be seen in Table 2. There 
was one statistically significant variable, which was 
the use of antithrombotic combination OR = 3.3 (95% 
CI: 1.3-8.5). The group of patients who used PPI drugs 
before endoscopy was performed had lower incidence 
of gastric mucosal injury OR = 0.2 (95% CI: 0.1-0.7).
Based on bivariate analysis, there was 3 independent 
variables had p < 0.25, which were age, antithrombotic 
combination, and use of proton pump inhibitor (PPI). 
Furthermore, we performed multivariate analysis to 
those variables. After multivariate analysis of those 
three variables had been performed, they were then 
included in the results as the most influencing factors in 
the occurrence of gastroduodenal mucosal injury. Age 
factor was still included in the final multivariate model, 
although statistically the p value > 0.05, as it was the 
most important factor in gastroduodenal mucosal 
injury. The final model of multivariate analysis could 
be seen in Table 3.
DISCUSSION
In this study, we found that the average age of 
research subjects was 63.5 ± 7.7 years old, from which 
43.2% patients were more than 65 years old. Similar 
result was reported in a study performed in Australia 
with average age of 61 years old.7 A meta-analysis also 
obtained similar average age of research subjects with 
this study, which was 63.3 years old.19 A study in Japan 
described that most patients’ age were more than 65 
years old, with average age of 68.9 ± 10.3 years old.8 
This was caused by the use of low-dose aspirin to 
prevent cardiovascular and cerebrovascular diseases 
which increased with the increase of age.
Table 1. Characteristics of research subjects
Characteristics
Erosive gastritis or 
peptic ulcer  
(49 subjects)
n (%)
Normal gastric 
mucosa  
(46 subjects) 
n (%)
Age (year old)
Age classification (year old)
< 50
50-64 
≥ 65 
63.8 ± 7.7 
3 (50)
18 (41.9)
28 (60.9)
63.2 ± 7.8
3 (50)
25 (58.1)
18 (39.1)
Sex
Male
Female
33 (54.1)
16 (47.1)
28 (45.9)
18 (52.9)
Dyspepsia complaints
Present
Absent
22 (44.9)
27 (58.7)
27 (55.1)
19 (41.3)
Antithrombotic combination
Yes
No
20 (71.4)
29 (43.3)
8 (28.6)
38 (56.7)
Warfarin use
Yes
No
2 (66.7)
47 (51.1)
1 (33.3)
45 (48.9)
NSAIDs use
Yes
No
4 (66.7)
45 (50.6)
2 (33.3)
44 (49.4)
Diabetes Mellitus
Yes
No
19 (54.3)
30 (50)
16 (45.7)
30 (50)
Helicobacter pylori Infection
Present
Absent
4 (66.7)
45 (50.6)
2 (33.3)
44 (49.4)
PPI administration
Yes
No
36 (45.6)
13 (81.3)
43 (54.4)
3 (18.7)
PPI: proton pump inhibitor; NSAIDs: non-steroidal anti-inflammatory drugs
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Table 2. Bivariate analysis 
Variables
Erosive gastritis or 
peptic ulcer 
n (%)
Normal gastric 
mucosa
n (%)
P OR (95% CI)
Age
≥ 65 years old
< 65 years old
28 (60.9)
21 (42.9)
18 (39.1)
28 (57.1)
0.121 2.1 (0.91 – 4.7)
Antithrombotic combination
Yes
No 20 (71.4)
29 (43.3)
8 (28.6)
38 (56.7)
0.023 3.3 (1.3 – 8.5)
Warfarin use
Yes
No
2 (66.7)
47 (51.1)
1 (33.3)
45 (48.9)
0.524 1.9 (0.2 – 21.9)
NSAIDs use
Yes
No
4 (66.7)
45 (50.6)
2 (33.3)
44 (49.4)
0.369 2.0 (0.3 – 11.2)
Diabetes mellitus
Yes
No
19 (54.3)
30 (50)
16 (45.7)
30 (50)
0.849 1.2 (0.5 – 2.7)
H. pylori infection
Present
Absent
4 (66.7)
45 (50.6)
2 (33.3)
44 (49.4)
0.369 2.0 (0.3 – 11.2)
PPI Administration
Yes
No
36 (45.6)
13 (81.3)
43 (54.4)
3 (18.7)
0.020 0.2 (0.1 – 0.7)
NSAIDs: non-steroidal anti-inflammatory drugs; PPI: proton pump inhibitor
Table 3. Multivariate analysis 
Variable P OR 95% CI
Age 0.059 2.4 0.97 – 5.82
Antithrombotic combination 0.009 3.8 1.40 – 10.49
PPI Administration 0.008 0.2 0.04 – 0.60
PPI: proton pump inhibitor
Forty-six patients (48.4%) did not have dyspepsia 
complaints during the administration of long-term 
low-dose aspirin. However, gastroduodenal mucosal 
injury was found in 58.7% patients who had no 
dyspepsia complaints. This showed that the absence of 
dyspepsia symptoms did not exclude the possibility of 
gastroduodenal mucosal injury. This was in accordance 
with previous studies. Yoemans et al identified that only 
20% patients with peptic ulcer had clinical symptoms of 
dyspepsia (nausea, regurgitation, bloating). The study 
also stated that that there was no significant difference 
of clinical symptoms of dyspepsia in ulcer and non-ulcer 
group.7 Niv et al conducted an oesophagoduodenoscopy 
study in 46 patients who used long-term low-dose aspirin 
(more than 3 months) and were asymptomatic and 
revealed that 22 patients (47.8%) had mucosal injury 
in the form of erosion or peptic ulcer.16
Diabetes mellitus is a disease which is commonly 
found as a risk factor of cardiovascular and 
cerebrovascular diseases.20 In this study, we found 
35 patients (36.8%) suffered from diabetes mellitus. 
This rate was higher in comparison to the population 
without cardiovascular or cerebrovascular incidence. 
A report from Badan Penelitian dan Pengembangan 
Kesehatan Kementrian Kesehatan (RISKESDAS) in 
year 2013 reported that the prevalence of diabetes 
mellitus was gained by interview, which was 1.5% in 
the year 2013. Meanwhile, the prevalence of diabetes 
mellitus based on doctors’ diagnosis in Indonesia was 
2.1%.21 Proportion of diabetes mellitus patients with 
coronary heart disease alone varied, which was 15.1–
21.4% patients based on registry data.22 In contrast, 
data of patients in India showed a rate similar to the 
results of this study, which was 30.4% and 39.1%.22 
It showed that diabetes mellitus as an important risk 
factor of cardiovascular disease.
From 95 research subjects, gastroduodenal mucosal 
injury was found in 49 patients (51.6%; 95% CI: 41.6-
61.7%), from which erosive gastritis was found in 38 
patients (40%; 95% CI: 30.2 – 49.9%) and peptic ulcer 
in 11 patients (11.6%; 95% CI: 5.2 – 18.0%). Yeomans 
et al also reported similar incidence rate, which was 
10.7% peptic ulcer and 63.1% erosion.7 Other study 
in India stated similar results, which revealed mucosal 
lesions in 28 from 47 patients (60%) with ischemic 
stroke and transient ischemic attacks who received 
long-term low-dose aspirin.23 In a study in Japan, it 
was found that 61.4% long-term low-dose aspirin users 
suffered from gastroduodenal mucosal injury and in 
18.8% patients, ulcers were identified.8 However, there 
was no association between the duration of aspirin use 
with the frequency of mucosal injury.8
The dose of aspirin being used in the study performed 
by Nema et al was 80-100 mg.8 While, in the study 
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conducted by Yeomans et al was 144 ± 9 mg. Subjects in 
this study also used the similar dose of aspirin, which was 
80-160 mg. A study which used patients’ data in England 
concluded that there was no significant difference of 
gastroduodenal mucosal injury in patients who used 
aspirin with the dose of 75 mg up to 300 mg.24 Mucosal 
injuries could even happen in aspirin administration with 
the dose of 10 mg for more than 3 months.25
The occurrence of gastroduodenal mucosal injury 
in aspirin users is through the similar mechanism of 
mucosal injury due to NSAIDs, which is systemic 
inhibition of endogen prostaglandin synthesis in 
the mucosa and direct irritation to gastric mucosa 
epithelial.26,27 During 6 years period of aspirin 
administration, it was reported that there was an 
increased incidence of upper gastrointestinal bleeding 
from 15 to 18, and further increased to 27 events 
in 100,000 population. Conversely, there was no 
significant increase in long-term NSAIDs users group.28 
This is because aspirin has particular characteristic 
compared to other NSAIDs group, including its acidic 
property and irreversible bond with cyclooxygenase 
(COX) enzyme, which both pathophysiology may 
worsen gastroduodenal mucosal injury.27,29
Based on bivariate analysis, it was found that 
patients with age group more than 65 years old had 
higher risk in the occurrence of gastroduodenal 
mucosal injury with OR = 2.1 (95% CI: 0.91-4.7). 
Yeomans et al reported more significant result, which 
was increased risk of 3.32 fold in age group more 
than 70 years old.7 Other studies in the United States 
revealed significant mean difference of age in group 
of patients who were low-dose aspirin users with 
gastrointestinal bleeding (70.9 ± 12.2 years old) with 
group without bleeding (66.5 ± 12.8 years old).30 Using 
data of low-dose aspirin users in England and Spain, 
Hernandez-Diaz et al identified that the incidence of 
gastrointestinal complication was 10-20 cases per 
1,000 patients per year and was higher in group with 
age more than 70 years old, affecting more than 100 
patients per 1,000 patients per year.31 In this study, age 
factor was included in the final model of multivariate 
analysis with adjusted OR = 2.4 (95% CI: 0.97-5.82).
Elderly patients who use long-term low-dose 
aspirin have a higher absolute risk of gastrointestinal 
complication compared to young aged patients because 
elderly patients have a baseline condition which is more 
prone to the incidence of gastrointestinal complication.32 
In old age, there are alterations in the gastrointestinal 
tract in the form of gastric mucosa atrophy and longer 
gastrointestinal transit time, therefore increases the 
risk of gastrointestinal complication in aspirin users.33 
Additionally, in old age, there is also sensory nerve 
disturbance, which causes the absence of clinical 
symptoms and delay in diagnosis.34
The study results suggested that antithrombotic 
combination increased the risk of gastroduodenal 
mucosal injury with OR = 3.3 (95% CI:1.3-8.5). 
Antithrombotic combination which was used in patients 
in this study was aspirin and clopidogrel. From the 
results of multivariate analysis, we also showed that 
antithrombotic combination, along with other risk factors 
including age more than 65 years old were important 
risk factors in the occurrence of gastroduodenal mucosal 
injury with OR = 3.8 (95% CI: 1.4-10.49).
Gracia et al informed that the risk of upper gastrointestinal 
bleeding in the administration of combination of aspirin 
and clopidogrel was 3.7 fold with an annual incidence of 
1.4-2.7 per 1,000 patients.35 This bleeding risk was also 
higher in comparison to patients who consumed aspirin 
only with RR = 2.08 (95% CI: 1.34-3.21).35 Hallas et al 
in their study in Denmark also reported increased risk of 
upper gastrointestinal bleeding in aspirin and clopidogrel 
users was 7.4 (95% CI: 3.5-15) compared to aspirin 
only group, which was 1.8 (95% CI: 1.5-2.1).10 Through 
this study, we may conclude that administration of 
combination of clopidogrel and aspirin had increased risk 
of gastroduodenal mucosal injury, not only gastrointestinal 
bleeding. This showed that there was possibility of 
antithrombotic combination was not only associated with 
the severity of gastroduodenal mucosal injury, but also the 
earlier onset of injury. Nonetheless, this needs to be proven 
in a study with prospective (cohort) design.
Three out of 95 research subjects (3.2%) consumed 
warfarin as co-medication with aspirin. We found no 
significant increased risk of gastroduodenal mucosal 
injury statistically in warfarin users as co-medication, 
although we obtained OR = 1.9 (95% CI: 0.2 – 21.9). 
Warfarin alone could increase major bleeding risk almost 
4 times compared to aspirin.36 Most studies also reported 
increased risk of gastrointestinal bleeding in aspirin 
and warfarin co-medication group compared to aspirin 
only group.10,35-39 Only two studies showed results that 
combination with warfarin did not increase the risk.40,41 
In this study, there was also no significant difference 
of the occurrence of gastroduodenal mucosal injury 
between aspirin and warfarin co-medication group and 
aspirin only group. However, statistically significance 
of proportion difference between these two groups was 
difficult to analyse due to the small number of research 
subjects who used warfarin as co-medication.
Six research subjects (6.3%) consumed NSAIDs in a 
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period of more than 7 days before upper gastrointestinal 
endoscopy procedure was performed. There was no 
significant increased risk of gastroduodenal mucosal 
injury statistically in NSAIDs combination group (OR 
= 2.0; 95% CI: 0.3-11.2). Statistical significance in this 
study was difficult to attain due to the small number of 
subjects who used NSAIDs as comedication (6.3%).
A study in England identified an increased risk in 
patients with NSAIDs and aspirin co-medication (RR = 
6.8; 95% CI: 4.5-10.3) compared to aspirin only group 
(RR = 2.9; 95% CI: 2.3-3.6).24 Hallas et al also reported 
higher proportion of NSAIDs users (36.2%) in upper 
gastrointestinal bleeding group in aspirin users compared 
to control group (10.7%).10 A cohort study with large 
sample size (27,694 subjects) also found an increased 
risk of upper gastrointestinal bleeding in NSAIDs and 
aspirin combination group (RR = 5.6; 95% CI: 4.4-7.0) 
compared to aspirin only (RR = 2.6; 95% CI: 2.2-2.9).15
Diabetes mellitus is an important risk factor of 
cardiovascular diseases and is considered equal to 
coronary heart disease.20 Thirty-five patients (36.8%) 
in this study suffered from diabetes mellitus. Diabetes 
was an independent risk factor of peptic ulcer 
bleeding with HR = 1.44 (1.11-1.86).42 Incidence of 
gastrointestinal complication was found to be higher 
in diabetic population patients. A prevalence study in 
Taiwan revealed that the incidence of peptic ulcer was 
higher in diabetic patients (14.8%) compared to non-
diabetic patients (8.5%) and was significantly different 
in statistics (p = 0.002).43 This study found low rate of 
gastrointestinal complaints in diabetic group (30.3 vs. 
35.4%; p = 0.006). This was due to autonomic nerves 
disturbance which leads to the absence of clinical 
symptoms during mucosal injury.43 Animal study also 
showed that the slow rate of gastric ulcer healing and 
increased risk of mucosal injury due to ulcerogenic 
drugs or stress in diabetic rats.42
There is no study to identify diabetes mellitus as 
risk factor of mucosal injury in long-term low-dose 
aspirin users yet. Although diabetes mellitus is an 
independent risk factors of peptic ulcer bleeding, this 
study did not find significant difference in proportion 
of patients with diabetes mellitus in the group with 
gastroduodenal mucosal injury compared to normal 
mucosal group (38.8 vs. 34.8; p = 0.849).
H. pylori infection was an independent risk factor 
of gastrointestinal ulcer bleeding with increased risk 
OR = 6.5 (95% CI: 3.4-12.6).44,45 In this study, there 
was 6 patients with H. pylori infection based on 
histopathology examination. Proportion of H. pylori 
infection in mucosal injury group was higher compared 
to normal mucosa group (OR = 2.0; 95% CI: 0.3-11.2), 
although it was not statistically significant (p = 0,369). 
Lanas et al described that H. pylori infection increased 
the risk of gastrointestinal bleeding in low-dose aspirin 
users with OR = 4.7 (95% CI: 2.0-10.9).20 In that study, 
patients suffering from H. pylori infection reached 
up to 40% from all research subjects.46 Meanwhile, 
Gracia Rodriguez reported different result, in which 
there was no difference of gastrointestinal bleeding 
risk in low-dose aspirin users with or without H. 
pylori infection (RR = 2.5 vs. 3.0).24 Yeomans et al 
identified that H. pylori infection increased the risk of 
duodenal ulcer in low-dose aspirin users (OR = 18.5; 
95% CI: 2.3-149.4), but not for gastric ulcer (OR = 2.3; 
95% CI: 0.7–7.8).7 It seemed that although H. pylori 
infection was independently associated with increased 
risk of gastrointestinal bleeding, its role in low-dose 
aspirin users is still controversial. In this study, the low 
incidence of H. pylori infection (6.3%) also became a 
reason to find significant association statistically.
In this study, majority of patients (83.2%) had 
received therapy of PPI drugs before gastrointestinal 
endoscopy procedure was performed. From 79 patients 
who consumed PPI, only 57% patients who actually 
complained of dyspepsia. This denoted the doctors’ 
concern when prescribing low-dose aspirin was 
probably the reason of high proportion of patients 
receiving PPI. From 79 patients consuming PPI, most 
patients consumed lansoprazole (93.7%) and the others 
had omeprazole (6.3%). In bivariate analysis, the use 
of PPI was proven to be protective to gastroduodenal 
mucosal injury in low-dose aspirin users with OR = 
0.02 (95% CI: 0.1-0.7). Multivariate analysis also 
showed the use of PPI as significant protective factor 
OR = 0.2 (95% CI: 0.04 – 0.60).
Many studies supported PPI as a protection for 
gastroduodenal mucosal injury. Ibanez et al described 
that PPI administration in low-dose aspirin users would 
decrease the risk of gastrointestinal bleeding from 
4.0 (3.2-4.9) to 1.1 (0.5-2.6).13 Study by Lanas A et 
al also revealed that PPI decreased the risk of upper 
gastrointestinal bleeding with OR = 0.09 (95% CI: 0.01-
0.69).46 Gracia et al reported that PPI administration 
for less than 1 month did not significantly decrease 
the risk of upper gastrointestinal bleeding (OR = 2.9; 
95% CI: 2.1-4.2); however, this became significant 
if administered for more than 1 month with OR = 
0.6 (95% CI: 0.4-1,0).24 Other studies exhibited that 
esomeprazole decreased risk of peptic ulcer.14,47,48
In comparison to other gastric acid anti-secreting 
drugs (H2 receptor antagonist), PPI had stronger 
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protection effect. Ng FH et al identified higher 
gastrointestinal bleeding in famotidine group compared 
to pantoprazole in aspirin users (20 vs. 0%).49 Lanas et al 
also reported that PPI administration was more effective 
compared to H2 receptor antagonist (OR = 0.009 vs. 
0.41).46 Other study by Gracia et al also exhibited 
that PPI was more superior compared to H2 receptor 
antagonist (OR = 0.6; 95% CI: 0.4-1.0) vs. 1.7 (95% 
CI: 1.2-2.4).24 Other studies by Chan et al compared 
the recurrence rate of peptic ulcer bleeding due to 
aspirin use in clopidogrel and placebo combination 
group with aspirin and esomeprazole combination 
group. In that study, they found lower recurrence rate in 
aspirin and esomeprazole combination group (1 vs. 13 
patients). This study concluded that PPI administration 
(esomeprazole) was superior compared to aspirin and 
clopidogrel combination group.50
Limitation of this study was this study used a cross-
sectional design; thus, direct causal relationship could 
not be concluded. This study used OR value as an 
output to describe the different possibility of mucosal 
injury in groups with and without exposure. However, 
due to the quite high prevalence being obtained 
(51.6%), the OR value became overestimated. Further 
studies with cohort or case-control design are needed 
to confirm causal relationship between risk factors with 
the occurrence of mucosal injury.
CONCLUSION
To sum up, gastroduodenal mucosal injury happened 
in more than half patients who used long-term low-dose 
aspirin. Antithrombotic combination increased the risk 
of mucosal injury. Meanwhile, PPI administration was 
effective in decreasing the aforementioned risk. Elderly 
aged group, combination with warfarin, use of NSAIDs 
as co-medication, and evidence of H. pylori infection 
had higher risk in the occurrence of gastroduodenal 
mucosal injury in long-term low-dose aspirin; although 
it was not statistically significant. Diabetes mellitus did 
not increase the risk of gastroduodenal mucosal injury 
in long-term low-dose aspirin users.
Further studies with cohort or case-control design are 
needed to confirm the causal relationship of influencing 
factors with the occurrence of gastroduodenal mucosal 
injury in long-term low-dose aspirin users. Studies 
comparing patients who consumed long-term low-dose 
aspirin to control groups (not aspirin users) may also 
be performed.
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